Nebivolol: novel beta-blocker with nitric oxide-induced vasodilation.
beta-blockers have been widely used for the treatment of hypertension, congestive heart failure and angina, as well as in the post-myocardial infarction population. Both beta(1) selective and nonselective agents are available. Nebivolol is a new highly beta(1 )selective antagonist with a nonadrenergic, nitric oxide potentiating vasodilatory property, which is unique among beta-blockers. In addition, nebviolol does not inhibit the increase in the heart rate response to exercise, which is unique among beta-blockers. Nebviolol has been tested successfully in double-blind, placebo-controlled trials in both hypertension and congestive heart failure.